These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

745 related articles for article (PubMed ID: 15531766)

  • 21. A randomized trial comparing clopidogrel versus ticlopidine therapy in patients undergoing infarct artery stenting for acute myocardial infarction with abciximab as adjunctive therapy.
    Parodi G; Sciagrà R; Migliorini A; Memisha G; Moschi G; Valenti R; Pupi A; Antoniucci D
    Am Heart J; 2005 Aug; 150(2):220. PubMed ID: 16086921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abciximab administration and clinical outcomes after percutaneous intervention for in-stent restenosis.
    Moustapha A; Assali AR; Sdringola S; Yusuf SW; Vaughn WK; Fish RD; Schroth GW; Krajcer Z; Rosales OR; Smalling RW; Anderson HV
    Catheter Cardiovasc Interv; 2002 Jun; 56(2):184-7. PubMed ID: 12112910
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial.
    Valgimigli M; Percoco G; Malagutti P; Campo G; Ferrari F; Barbieri D; Cicchitelli G; McFadden EP; Merlini F; Ansani L; Guardigli G; Bettini A; Parrinello G; Boersma E; Ferrari R;
    JAMA; 2005 May; 293(17):2109-17. PubMed ID: 15870414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
    Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Lansky AJ;
    N Engl J Med; 2002 Mar; 346(13):957-66. PubMed ID: 11919304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of abciximab on clinical and angiographic restenosis in patients with non-ST-segment elevation acute coronary syndromes.
    Iijima R; Ndrepepa G; Mehilli J; Dirschinger J; Pache J; Seyfarth M; Schömig A; Kastrati A
    Am J Cardiol; 2008 May; 101(9):1226-31. PubMed ID: 18435948
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
    Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial.
    Marmur JD; Mitre CA; Barnathan E; Cavusoglu E
    Am Heart J; 2006 Nov; 152(5):876-81. PubMed ID: 17070148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized study comparing same-day home discharge and abciximab bolus only to overnight hospitalization and abciximab bolus and infusion after transradial coronary stent implantation.
    Bertrand OF; De Larochellière R; Rodés-Cabau J; Proulx G; Gleeton O; Nguyen CM; Déry JP; Barbeau G; Noël B; Larose E; Poirier P; Roy L;
    Circulation; 2006 Dec; 114(24):2636-43. PubMed ID: 17145988
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
    Claeys MJ; Van der Planken MG; Bosmans JM; Michiels JJ; Vertessen F; Van Der Goten P; Wuyts FL; Vrints CJ
    Eur Heart J; 2005 Mar; 26(6):567-75. PubMed ID: 15618034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glycoprotein IIb/IIIa receptor inhibition with abciximab during percutaneous coronary interventions increases the risk of bleeding in patients with impaired renal function.
    Pinkau T; Ndrepepa G; Kastrati A; Mann JF; Schulz S; Mehilli J; Schömig A
    Cardiology; 2008; 111(4):247-53. PubMed ID: 18434733
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of the platelet glycoprotein IIb/IIIa inhibitor abciximab in Chinese patients undergoing high-risk angioplasty.
    Chen YH; Chen JW; Wu TC; Ding PY; Wang SP; Chang MS
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jan; 63(1):8-15. PubMed ID: 10645045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial).
    Stuckey TD; Stone GW; Cox DA; Tcheng JE; Garcia E; Carroll J; Guagliumi G; Rutherford BD; Griffin JJ; Turco M; Lansky AJ; Mehran R; Fahy M; Brodie BR; Grines CL;
    Am J Cardiol; 2005 Jan; 95(1):1-7. PubMed ID: 15619385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up.
    Montalescot G; Antoniucci D; Kastrati A; Neumann FJ; Borentain M; Migliorini A; Boutron C; Collet JP; Vicaut E
    Eur Heart J; 2007 Feb; 28(4):443-9. PubMed ID: 17251257
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
    Cuisset T; Frere C; Quilici J; Morange PE; Mouret JP; Bali L; Moro PJ; Lambert M; Alessi MC; Bonnet JL
    JACC Cardiovasc Interv; 2008 Dec; 1(6):649-53. PubMed ID: 19463379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of abciximab on coronary restenosis in diabetic patients undergoing elective paclitaxel-eluting stent implantation. A prospective, randomized, placebo-controlled study.
    De Luca L; Sardella G; De Persio G; Petrolini A; Fedele F
    Acute Card Care; 2008; 10(2):93-9. PubMed ID: 18568571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
    Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
    Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.
    Ibbotson T; McGavin JK; Goa KL
    Am J Cardiovasc Drugs; 2003; 3(5):381-6. PubMed ID: 14728074
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators.
    Kleiman NS; Lincoff AM; Kereiakes DJ; Miller DP; Aguirre FV; Anderson KM; Weisman HF; Califf RM; Topol EJ
    Circulation; 1998 May; 97(19):1912-20. PubMed ID: 9609084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Guagliumi G; Stone GW; Cox DA; Stuckey T; Tcheng JE; Turco M; Musumeci G; Griffin JJ; Lansky AJ; Mehran R; Grines CL; Garcia E
    Circulation; 2004 Sep; 110(12):1598-604. PubMed ID: 15353506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prophylactic abciximab in elective coronary stenting: results of a randomized trial.
    Tamburino C; Russo G; Nicosia A; Galassi AR; Foti R; Scriffignano V; Kereiakes DJ; Giuffrida G
    J Invasive Cardiol; 2002 Feb; 14(2):72-9. PubMed ID: 11818641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.